BioMarin Pharmaceutical Inc. expects a strong end to 2026 and early 2027 with important milestones including Phase 1/2 data for BMN 351 in Duchenne muscular dystrophy and a possible approval of Voxzogo for hypochondroplasia in the first half of 2027. The company raised its 2026 revenue guidance to $3.88-$3.93 billion, reflecting confidence in its rare disease drug portfolio. These developments have renewed investor interest and highlight BioMarin's attractive risk/reward profile in the rare disease therapeutics market.
BioMarin Pharmaceutical's outlook for 2026-2027 comes as Pluang data shows 54 of 95 health-sector US stocks rose today. Illumina led gains with a price of USD 247.90 and a 3.46% increase. This snapshot is as of Sep 21, 2026 21:11 WIB.
Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...
Morgan Stanley upgraded NNN REIT from Neutral to Overweight due to its stable income and strong financial health. The REIT boasts a 99.1% occupancy rate and 97.5% fixed-rate debt, ensuring steady rental income and protection against interest rate hik...
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Nebius Group has been upgraded to a buy rating following a significant improvement in its operating margin, which nearly broke even in the second fiscal quarter after a -32% loss in the first quarter. This turnaround is attributed to capacity expansi...
